…you feel that Gilead would sit on the sidelines while 50% of their market disappears? I don't think so.
Two comments: i) the 50% number is not mine; and ii) the all-oral GT1 market we’re talking about does not belong to GILD; rather, GILD will be entering this market around the same time as ABBV/ENTA.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”